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walk test (30.4%). Amongst 1198 PReP-participants [69.0 
± 10.6  years, 25.3% female, New York Heart Associa-
tion (NYHA) class 2.4  ± 0.5, LVEF 35.3 ± 7.2%], ID was 
found in 42.5% (previously unknown in all), and anaemia 
in 18.9% (previously known in 4.8%). ID was associated 
with female gender, lower body weight and haemoglobin, 
higher NYHA class and natriuretic peptide (NP) levels 
(all p < 0.05). ID was also more common in anaemic than 
non-anaemic patients (p < 0.0001), and 9.8% of PrEP-par-
ticipants had both, ID and anaemia. On spiroergometry, 
ID independently predicted maximum exercise capacity 
even after multivariable adjustment, including anaemia 
(p = 0.0004). In all PrEP-participants, ID predicted reduced 
physical performance (adjusted for age, gender, anaemia, 
serum creatinine, C-reactive protein, LVEF, and NP level).
Conclusions Despite high prevalence, ID was previously 
unknown in all PrEP-participants, and anaemia was often 
unappreciated. Given the clinical relevance, treatability, 
and independent association with reduced physical perfor-
mance, ID should be considered more in real-world ambu-
latory healthcare settings and ID-screening be advocated to 
cardiologists in such populations.
Keywords Iron deficiency · Anaemia · Exercise 
capacity · Heart failure · Prevalence
Introduction
Besides anaemia, iron deficiency (ID) has more recently 
been recognized as a separate clinically relevant co-mor-
bidity in patients with heart failure (HF) and other cardio-
vascular illnesses, with serious consequences for patient 
well-being and outcomes [1, 2]. The pivotal importance of 
iron is based on its essential role in oxygen transport, and 
Abstract 
Background Iron deficiency (ID) and anaemia are com-
mon in heart failure (HF). The prospective, observational 
PReP registry (Prävalenz des Eisenmangels bei Patienten 
mit Herzinsuffizienz) studied prevalence and clinical impact 
of ID and anaemia in HF outpatients attending cardiology 
practices in Germany.
Methods and results A total of 42 practices enrolled con-
secutive patients with chronic HF [left ventricular ejection 
fraction (LVEF) ≤45%]. ID was defined as serum ferri-
tin <100  µg/l, or serum ferritin ≥100  µg/l/<300  µg/l plus 
transferrin saturation <20%, and anaemia as haemoglo-
bin <13  g/dl (12  g/dl) in men (women). Exercise capac-
ity was assessed using spiroergometry (69.4%) or 6-min 
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its central role in processes maintaining cellular energy in 
high-energy demanding tissues like cardiac muscle [3–5].
ID can be classified into absolute ID, reflecting depleted 
iron stores, and functional ID, where iron delivery to target 
cells is hampered despite normal or overly abundant iron 
stores [6]. In healthy subjects, ID is generally diagnosed 
using a serum ferritin cut-off level <30 µg/l for absolute ID 
[7]. Because ferritin is also an acute phase reactant, pro-
inflammatory activity increases its synthesis, thus render-
ing the diagnosis of ID more difficult in diseases associated 
with chronic subclinical inflammation. A ferritin cut-off 
value <100  µg/l is currently considered diagnostic for ID 
in patients with HF irrespective of transferrin saturation 
(TSAT). Alternatively, a cut-off value <300  µg/l together 
with a TSAT <20% may be used [8, 9]. Reduced TSAT is 
viewed as an indicator of insufficient iron availability for 
metabolizing cells [10].
Dependent on the various ID definitions, the prevalence 
of ID has been estimated between 13 and 34% with higher 
incidence rates among anaemic patients [11, 12]. Using the 
above diagnostic criteria, Jankowska et  al. recently docu-
mented a 37% prevalence of ID among 546 patients with 
chronic systolic HF [13] and identified female gender, 
advanced disease (New York Heart Association class, and 
elevated plasma N-terminal pro-B-type natriuretic pep-
tide (NT-proBNP) and serum high-sensitivity C-reactive 
protein levels as independent predictors of a higher likeli-
hood of ID in a relatively young and predominantly male 
HF population. Little is known about the prevalence and 
clinical impact of ID with or without concurrent anaemia 
in a clinically stable, community-dwelling outpatient pop-
ulation with chronic HF. The prospective observational 
PReP registry (Prävalenz des Eisenmangels bei Patienten 
mit Herzinsuffizienz) was created to study prevalence and 
clinical impact of ID and anaemia in a real-world setting of 
ambulatory patients with HF.
Methods
Between November 2010 and March 2012, ambulatory 
patients with chronic HF who presented at one of 42 office-
based cardiologist practices in Germany were recruited into 
the prospective PrEP registry. All male and female patients 
aged 18 years and older were eligible, provided a left ven-
tricular ejection fraction of 45% or less was documented on 
echocardiography during the enrolment visit and signs and 
symptoms of chronic heart failure were present. All patients 
gave written informed consent to the analysis of their pseu-
donymized clinical and laboratory data as part of the PReP 
registry. Practices were asked to include patients consecu-
tively. None of the participating cardiologists reported any 
patients who a priori declined participation. However, the 
study protocol did not foresee entry of all screened patients 
into a screening and enrolment log sheet. Exclusion crite-
ria were coronary interventions of any kind within the past 
6  months and planned coronary interventions, evidence 
of acute or chronic infectious or inflammatory conditions 
from routine laboratory assessment, malignant disease or 
gastric or duodenal ulcer with or without active bleeding, 
and lack of written informed consent. The ethics commit-
tee of the Bavarian Chamber of Physicians, Munich, Ger-
many, approved the study, and all patients provided written 
informed consent. The study was conducted in accordance 
with the Declaration of Helsinki.
A total of 1602 patients with chronic symptomatic HF 
were enrolled. Four hundred and four of these partici-
pants had to be excluded from the final data set and sub-
sequent analysis due to protocol violations (particularly in 
one centre whose entire patient cohort had to be excluded 
because of insufficient or ambiguous data documentation) 
or because essential data were missing. Patient baseline 
assessment included a standardized HF history regarding 
HF aetiology (classified as ischaemic or non-ischaemic) 
and co-morbidities.
All patients underwent a standardized clinical evalu-
ation, including physical examination, determination of 
NYHA class, determination of body weight, and deter-
mination of the heart rate from the electrocardiogram and 
of blood pressure by the Riva-Rocci method. In addition, 
patients underwent semiquantitative assessment of their 
volume status, in which peripheral oedema was classified 
as absent, mild, or significant. Blood samples were drawn 
from an antecubital vein in the morning for the assess-
ment of a full blood count and clinical chemistry, includ-
ing parameters of iron metabolism [serum ferritin, transfer-
rin, and transferrin saturation (TSAT)] and kidney function 
(creatinine).
Renal dysfunction was diagnosed if the glomerular fil-
tration rate was below 60  ml/min/1.73  m2, diabetes mel-
litus, if patients reported a history of diabetes or were on 
anti-diabetic drugs, and chronic obstructive pulmonary 
disease (COPD), if patients were on anti-obstructive phar-
macotherapy or reported that COPD had been previously 
diagnosed. A history of depression was assumed if patients 
reported a previous respective physician diagnosis or were 
undergoing any specific antidepressant therapy. The diag-
nosis of restless legs was documented if patients reported 
that this condition had been previously diagnosed. Anaemia 
was defined according to World Health Organization crite-
ria as haemoglobin level <12 g/dl in women and <13 g/dl 
in men [14]. ID was defined as serum ferritin <100 µg/l, or 
serum ferritin ≥100  µg/l and <300  µg/l with TSAT <20%. 
For natriuretic peptide assessment, either determination of 
B-type natriuretic peptide (BNP) or N-terminal-proBNP 
(NT-proBNP) was permitted according to local standards. 
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Assessment of exercise capacity was performed either 
by spiroergometry testing or a 6-min corridor walk test, 
depending on local circumstances and availability. Exer-
cise capacitly was categorized as reduced, if patients per-
formed below the median of the respective test, i.e., below 
the median exercise capacity at spiroergometry or below 
the median walking distancene during the 6-min walk test, 
respectively.
Statistical analyses
Continuous variables are given as means with standard 
deviations. Non-normally distributed variables (serum 
ferritin, serum creatinine, serum C-reactive protein, and 
natriuretic peptides) were log-transformed to achieve nor-
mal distribution before analysis. Student’s t test and analy-
sis of variance (ANOVA) with Fisher’s post-hoc test were 
used to test for between-group differences. Categorical var-
iables were expressed as numbers with percentages and the 
Chi-square test was used to test for inter-group proportion 
differences. Simple regression was used to analyse the first-
line associations between continuous variables.
Univariate and multivariate logistic regression mod-
els were used to identify clinical determinants of exercise 
capacity in patients with chronic HF. The analyses included 
continuous and dichotomized variables of the parameters 
age, gender, NYHA class, LVEF, natriuretic peptide levels, 
the presence of anaemia, and the presence of ID. All statis-
tical analyses were performed using StatView version 5.0 
for Mac (Abacus Concepts, Berkeley, California). All tests 
were two-sided. P values of <0.05 were considered statisti-
cally significant.
Results
The final data set comprised 1198 patients, 25.7% of whom 
were female. Baseline characteristics are given in Table 1. 
Patients were elderly, with a mean age of 69.0  ± 10.6 years. 
HF aetiology was predominantly ischaemic (62.4%). The 
NYHA distribution was n = 730 (60.9%) for NYHA class 
II, n = 457 (38.1%) for class III, and n = 11 (0.01%) for 
class IV. HF medications included angiotensin-converting 
enzyme inhibitors (68.6%), angiotensin receptor blockers 
(24.6%), beta-blockers (86.1%), mineralocorticoid receptor 
antagonists (39.1%), and digitalis (18.4%). A total of 87.9% 
of all patients received either an angiotensin-converting 
enzyme inhibitor or an angiotensin receptor blocker, and 
64 patients (5.3%) received both. Diuretics were prescribed 
in 76.3% of the patients. A total of 864 patients (69.6%) 
underwent spiroergometry and the remaining 334 patients 
(30.4%) completed a 6-min walk test.
Prevalence of iron deficiency
ID was present in 509 (42.5%) of the PrEP-participants and 
not previously known in any of them. None of the patients 
had a history of iron supplementation of any kind. Com-
pared with PrEP-participants without ID, these patients 
had lower body weight (p = 0.01), haemoglobin levels 
(<0.0001) and mean corpuscular haemoglobin volume 
(p < 0.0001), and higher platelet count (p < 0.0001), NYHA 
class (p = 0.0003), and B-type natriuretic peptide (BNP) 
(p = 0.01) or N-terminal pro-B-type natriuretic peptide 
(NT-proBNP) values (p = 0.0015, Table 1). By contrast, no 
differences were recorded for age, resting heart rate, blood 
pressure, LVEF, leukocyte count, C-reactive protein, or 
serum creatinine (all p > 0.05).
Among patients who reported to suffer from restless legs 
syndrome and those with a history of depression, ID was 
significantly more prevalent than in the group without ID 
(Table 1, p = 0.03 and p = 0.002, respectively). No such dif-
ferences were found regarding hypertension, diabetes, renal 
dysfunction, or chronic obstructive pulmonary disease.
Prevalence of anaemia
Two hundred and twenty six (18.9%) of the PrEP-partici-
pants presented with anaemia. Despite high prevalence, this 
co-morbidity was known prior to enrolment only in 4.8%. 
None of the patients had received erythropoietin or blood 
transfusion for the treatment of anaemia. Anaemic patients 
were more likely to have concomitant ID than non-anaemic 
patients (p = 0.02), and anaemia and ID were concomitantly 
present in 117 (9.8%) of the patients.
Baseline haemoglobin strongly correlated with serum 
ferritin (r = 0.16, p < 0.0001), TSAT (r = 0.26, p < 0.0001), 
C-reactive protein (r = −0.15, p < 0.0001), and serum cre-
atinine (r = −0.14, p < 0.0001). When analysed separately, 
there was a highly significant association between hae-
moglobin and serum ferritin in patients with ID (r = 0.16, 
p = 0.0004), whereas in patients without ID, this association 
was only of borderline significance (r = −0.09, p = 0.03). 
No corresponding associations were noted between hae-
moglobin and TSAT, C-reactive protein, or serum creatine 
after splitting the data set into patients with vs. without ID. 
In univariable analysis, the presence of anaemia, ID, or 
both was associated with significantly higher NYHA class 
(Figs. 1 and 2).
Predictors of exercise capacity
Maximum exercise capacity as assessed by spiroergometry 
was significantly lower in patients with ID (p = 0.0004), 
while regarding the 6-min walking distance, there was no 
significant difference in patients with versus without ID 
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(p = 0.24). Using logistic regression, we found that age, 
gender, body weight, systolic and diastolic blood pressure, 
NYHA class, the presence of oedema, LVEF, the presence 
of anaemia, haemoglobin, the presence of ID, serum fer-
ritin, transferrin saturation (TSAT), serum creatinine, a 
history of chronic kidney disease, and a history of anae-
mia all predicted lower exercise capacity (all p < 0.05, 
Table 2). The same was true for BNP or NT-proBNP val-
ues above the diagnostic cut-off for non-acute HF (>35 pg/
ml and >125  pg/ml, respectively). After adjustment for 
Table 1  Baseline 
characteristics of the total study 
population and of patients with 
versus without iron deficiency
Values are mean ± standard deviation or number of patients (%), apart from biomarker values which are 
reported as median [interquartile-range]
BP Blood pressure, BNP B-type natriuretic peptide, COPD chronic obstructive pulmonary disease, LVEF 
left ventricular ejection fraction, NT-proBNP N-terminal pro-B-type natriuretic peptide, NYHA New York 
heart association, TSAT transferrin saturation
*Student’s t test and analysis of variance (ANOVA) with Fisher’s post-hoc test
**COPD chronic obstructive pulmonary disease, either requiring bronchiolytic treatment or patient-
reported previous diagnosis
a Hypertension: sitting blood pressure >140/90 mmHg or history of hypertension
b Anaemia: haemoglobin <12 mg/dl (females) or < 13 mg/dl (males)
c Renal dysfunction: estimated glomerular filtration rate <60 mL/min/1.73 m2.
d Diabetes mellitus: history of diabetes mellitus
e History of depression: either patient-reported physician diagnosis of depression or on antidepressant ther-
apy
f Restless leg syndrome: patient-reported previous diagnosis
All patients Patients with 
iron deficiency 
(n = 509)
Patients without iron 
deficiency (n = 689)
P*
Demographics
 Age (years) 69.0 ± 10.6 69.0 ± 11.2 69.0 ± 10.1 0.99
 Male gender (%) 74.3 66.4 80.1 <0.0001
 Body weight (kg) 84.9 ± 17.9 83.3 ± 18.4 86.0 ± 17.5 0.01
 Heart rate  (min−1) 71.7 ± 13.0 72.4 ± 12.8 71.3 ± 13.1 0.15
 Systolic BP (mmHg) 129 ± 20 129 ± 21 129 ± 19 0.64
 Diastolic BP (mmHg) 78 ± 11 77 ± 11 78 ± 11 0.46
HF characteristics
 Ischaemic aetioogy (%) 62.4 64.4 60.8 0.20
 NYHA class 2.4 ± 0.5 2.5 ± 0.5 2.4 ± 0.5 0.0003
 LVEF (%) 35.3 ± 7.2 35.0 ± 7.5 35.6 ± 7.0 0.17
Laboratory assessments
 Haemoglobin (g/dl) 13.9 ± 1.6 13.6 ± 1.7 14.2 ± 1.5 <0.0001
 Leukocytes (µl− 1) 7617 ± 3793 7757 ± 3491 7505 ± 4015 0.35
 Platelets (µl− 1) 214,690 ± 64,043 223,440 ± 68,593 208,227 ± 59,695 <0.0001
 Serum ferritin (µg/l) 196 ± 197 77.1 ± 53.6 285 ± 218 <0.0001
 TSAT (%) 24.2 ± 9.3 19.1 ± 8.6 28.2 ± 7.7 <0.0001
 Serum creatinine (mg/dl) 1.2 ± 0.6 1.2 ± 0.4 1.2 ± 0.6 0.05
 CRP (mg/dl) 1.9 ± 5.7 2.0 ± 4.3 1.8 ± 6.5 0.004
 BNP (pg/ml) [n = 392] 346 ± 623 442 ± 675 282 ± 577 0.01
 NT-proBNP (pg/ml) [n = 810] 1449 ± 1906 1690 ± 2252 1263 ± 1567 0.002
Co-morbidities and risk factors
  Anaemia (%)b 18.9 23.0 15.8 0.02
 Hypertension (%)a 68.7 69.2 68.4 0.09
 Renal dsyfunction (%)c 22.7 23.0 22.5 0.84
 COPD (%)** 8.9 10.6 7.7 0.08
 Diabetes mellitus (%)d 30.0 32.4 28.2 0.11
 History of depression (%)e 5.7 8.0 3.9 0.002
 Restless legs syndrome (%)f 2.6 3.7 1.7 0.03
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age, gender, the presence of anaemia, creatinine, LVEF, 
and natriuretic peptide levels, the presence of ID remained 
an independent predictor of reduced exercise capac-
ity [odds ratio (OR) 1.323, 95% confidence interval (CI) 
1.009–1.735, p = 0.04]. Likewise, the presence of anaemia 
independently predicted reduced exercise capacity after 
adjusting for age, gender, creatinine, CRP, LVEF, the pres-
ence of ID, and natriuretic peptide levels (OR 1.939, 95% 
CI 1.356–2.773, p = 0.0003).
Discussion
To our knowledge, the PReP Registry constitutes so far 
the largest prospective cohort study in ambulatory patients 
with chronic stable systolic HF evaluating the prevalence 
and clinical impact of ID and anaemia in a real-world 
healthcare setting. With 42.5%, ID proved highly prevalent 
in this population of outpatients taken care of in office-
based cardiology practices across Germany. With 18.9% 
the proportion of anaemia was significantly lower than that 
of ID. Interestingly, the overlap between the two popula-
tions was smaller than one might have expected, since only 
every second anaemic patient also presented with ID at the 
same time. Independent of the presence of anaemia, ID pre-
dicted lower physical performance irrespective of the exer-
cise test used, i.e., a walking distance or maximum exercise 
- - + + Anaemia











Fig. 1  NYHA class according to baseline status being iron-deficient, 
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Fig. 2  NYHA class according to baseline status being iron-deficient, 
anaemic, both or none of the two, devided by gender. Male blue bars, 
female red bars. Number above the bars represents n numbers in each 
group
Table 2  Univariable and multivariable logistic regression models to 
predict baseline exercise capacity among 1198 patients with HF with 
reduced ejection fraction
BP blood pressure, BNP B-type natriuretic peptide, COPD chronic 
obstructive pulmonary disease, LVEF left ventricular ejection frac-
tion, NT-proBNP N-terminal pro-B-type natriuretic peptide, NYHA 
New York Heart Association, TSAT transferrin saturation
*Adjusted for age, gender, current anaemia, log serum creatinine, log 
C-reactive protein, LVEF, and BNP/NT-proBNP above diagnostic 
cutoff for non-acute HF
**Adjusted for age, gender, log serum creatinine, log C-reactive pro-
tein, LVEF, the presence of ID, and BNP/NT-proBNP above diagnos-
tic cutoff for non-acute HF
Variable Odds ratio (95% CI) p
Univariable models
 Age (1 year increase) 1.085 (1.071–1.100) <0.0001
 Gender (female) 3.788 (2.830–5.072) <0.0001
 Systolic BP (1 mmHg increase) 0.992 (0.986–0.998) 0.007
 Diastolic BP (1 mmHg increase) 0.973 (0.962–0.983) <0.0001
 Ischaemic heart disease (present) 1.143 (0.904–1.445) 0.27
 NYHA class (1 class increase) 3.246 (2.547–4.136) <0.0001
 LVEF (1 unit increase) 0.968 (0.953–0.984) <0.0001
 Oedema (present) 2.254 (1.699–2.989) <0.0001
 Iron deficiency (present) 1.547 (1.227–1.950) 0.0002
 Haemoglobin (1 g/dl increase) 0.693 (0.640–0.751) <0.0001
 Current anaemia (present) 2.361 (1.732–3.219) <0.0001
 History of anaemia (present) 2.597 (1.424–4.736) 0.002
 Ferritin (10 µg/l increase) 0.991 (0.985–0.998) 0.007
 Log serum ferritin (1 SD increase) 0.789 (0.702–0.887) <0.0001
 TSAT (1 unit increase) 0.985 (0.970–0.999) 0.04
 BNP/NT-proBNP above diagnostic 
cutoff for non-acute HF (present)
2.379 (1.622–3.492) <0.0001
 Log serum creatinine (1 SD 
increase)
1.323 (1.172–1.493) <0.0001
 Log C-reactive protein (1 SD 
increase)
1.208 (1.076–1.355) 0.001
 History of diabetes mellitus 
(present)
1.155 (0.901–1.481) 0.26
 History of COPD (present) 1.150 (0.771–1.715) 0.49




 Iron deficiency (present)* 1.323 (1.009–1.735) 0.04
 Anaemia (present)** 1.939 (1.356–2.773) 0.0003
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capacity on spiroergometry below the median, which high-
lights the functional importance of this co-morbidity for the 
patients. Likewise, the presence of anaemia also predicted a 
significantly lower maximum exercise capacity.
Prevalence and possible consequences of iron deficiency
Prevalence and possible consequences of ID complicating 
HF have more recently been attracting increasing atten-
tion. Many (mostly secondary) analyses were published 
that addressed the prevalence of ID in HF cohorts often 
derived from other clinical studies [13, 15–17]. In this con-
text, Opasich et al. demonstrated, e.g., that the majority of 
patients with chronic HF and low haemoglobin levels had 
anaemia of chronic disease, and nearly, all had deficient 
iron supply for erythropoiesis and/or blunted endogenous 
erythropoietin production [15]. Among more than 500 
ambulatory patients with stable HF, Jankowska et al. found 
an ID rate of 32 and 57% in anaemic and non-anaemic sub-
jects, respectively [13]. Schou et al. using the same cut-off 
criteria as Jankowska et al. to define ID, found among Dan-
ish outpatients with characteristics similar to those of the 
PrEP-participants (25% female, NYHA III-IV, mean LVEF 
32%) an ID prevalence of 45% and thus very comparable 
to our findings [17]. Our findings from the PrEP registry 
regarding ID prevalence are thus in accordance with pub-
lished data from several clinical cohorts as well as from 
smaller outpatient cohorts. The PrEP results also corre-
spond to a recent report from the Studies Investigating Co-
morbidities Aggravating Heart Failure (SICA-HF): [18]. 
Among outpatients with systolic HF, 30% presented with 
anaemia and 45% with ID. Remarkably, and also in line 
with our observations, exercise capacity decreased in par-
allel to decreasing haemoglobin levels (r = 0.24, p < 0.001) 
in SICA-HF. Furthermore, exercise capacity proved sig-
nificantly lower in 19% of the patients who presented with 
both, anaemia and ID, compared with those with either ID 
or anaemia, respectively.
Even though the prevalence of restless legs syndrome 
or a history of depression was low, the proportion of ID 
among affected PrEP-participants was significantly higher 
than among patients without ID. This finding is in line 
with the previous observations by Allen et al., who found 
a 23.9% prevalence of this syndrome among 251 first-pre-
senters with ID and anaemia and no treatment for restless 
legs syndrome [19]. A similar association was previously 
also suggested for depression [20]. In conjunction with the 
previous findings, our present results indicate the possibil-
ity of adverse neuro-psychiatric effects of ID as yet another 
intriguing facet of its complex systemic sequels. However, 
prospective research needs to ascertain these interrelations, 
since our observation of a higher prevalence of patient-
reported restless leg syndrome or a history of depression in 
patients with ID does not establish causality, as it is subject 
to various kinds of bias. In particular, future studies need to 
employ appropriate validated tools to evaluate and quantify 
both conditions at the time of study enrolment rather than 
rely on patients’ history.
Therapeutic options in iron deficiency and anaemia
Common clinical practice treatment options of anaemia in 
patients with HF, which might be considered after exclu-
sion of treatable/reversible causes (e.g., gastrointestinal 
bleeding), include application of erythropoietin and its 
derivatives, blood transfusions, or iron administration. 
However, the Reduction of Events in Heart Failure trial 
(RED-HF) using darbepoetin-alfa in anaemic patients with 
HF recently ended neutral, [21] and blood transfusions 
should be restricted to selected symptomatic patients with 
very low haemoglobin levels, predominantly those <8  g/
dl, leaving repletion of iron stores as the only promising 
treatment option with anaemia and ID that may be applied 
routinely in clinical practice. Our findings of a high preva-
lence of ID not always coincide with anaemia among PrEP-
participants and the independent association of ID with 
reduced exercise capacity in our cohort buttress applica-
bility of the current guideline recommendation regarding 
repletion of ID also in the outpatient setting. They suggest 
that iron substitution should be considered in symptomatic 
outpatients with chronic stable HF with reduced ejection 
fraction and ID and anaemia, but also, if there is no con-
comitant anaemia [2].
Using the same definition of ID as employed in the PrEP 
registry, the Ferinject Assessment in patients with IRon 
deficiency and chronic Heart Failure (FAIR-HF) trial ran-
domized patients with symptomatic HF and a LVEF ≤40% 
(or ≤45% and NYHA III) with ID and haemoglobin lev-
els between 9.5 and 13.5  g/dl to intravenous ferric car-
boxymaltose or saline [22]. After 24  weeks, self-reported 
patient global assessment had improved significantly more 
often in patients receiving ferric carboximaltose (50% vs 
28%, p < 0.001), and various secondary endpoints, includ-
ing NYHA class and quality of life, had also improved 
[23]. Using a similar study design, the ferric Carboxy-
maltOse evaluatioN on perFormance in patients with IRon 
deficiency in coMbination with chronic Heart Failure 
(CONFIRM-HF) study extended these findings in an out-
patient population with ID and similar characteristics to an 
observation period of 52  weeks [24]. Importantly, hospi-
tal admissions for worsening HF, which constituted a pre-
defined secondary endpoint, were significantly reduced in 
CONFIRM-HF. The Effect of Ferric Carboxymaltose on 
Exercise Capacity in Patients With Iron Deficiency and 
Chronic Heart Failure (EFFECT-HF) trial, even though 
open label, further extended these findings by showing 
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that intravenous iron therapy with ferric carboxymaltose 
improves exercise capacity as assessed using spiroergome-
try [25]. A recent meta-analysis involving five trials, which 
evaluated intravenous iron therapy in iron-deficient patients 
with systolic heart failure, confirmed that this treatment 
improves clinical outcomes, exercise capacity, and qual-
ity of life, and to alleviate HF symptoms [26]. In line with 
these results, another meta-analysis showed that iron sup-
plementation reduced the need for blood transfusions and 
increased haemoglobin levels in patients with chronic kid-
ney disease or in the peri-partal period [27]. The recently 
published Oral Iron Repletion effects ON Oxygen UpTake 
in Heart Failure (IRONOUT) trial has underscored miss-
ing benefit of oral iron therapy, as no increase in exercise 
capacity and only a minimal increase in serum ferritin level 
were noted after 12 weeks of therapy [28].
Against this background, current guidelines for the man-
agement of HF advocate the repletion of ID with the inclu-
sion criteria of FAIR-HF as defining features for patients 
eligible for treatment [2]. In addition, the guidelines state 
that blood biochemistry parameters should be regularly 
assessed to “detect reversible/treatable causes of HF (e.g., 
hypocalcaemia, thyroid dysfunction) and co-morbidities 
(e.g., iron deficiency)”. With regard to anaemia, the guide-
lines list “chronic HF, haemodilution, iron loss or poor uti-
lization, renal failure, chronic disease, (and) malignancy” 
as potential reasons for anaemia development, and recom-
mend to perform a “diagnostic work-up” and to “consider 
treatment” [2]. A recent French position paper states that 
iron supplementation should be considered “for all patients 
with chronic HF or hospitalized for acute decompensa-
tion of chronic HF with biological evidence of iron insuf-
ficiency” [29].
Limitations
Findings of this study should be interpreted in the light of 
its limitations. First, the PrEP registry derived all study data 
from informations obtained during routine patient care. 
Patient phaenotyping was, therefore, not strictly stand-
ardized and performed according to local circumstances, 
which precluded, e.g., the use of uniform exercise testing or 
determination of just one natriuretic peptide. The diagno-
sis of co-morbidities as restless leg syndrome, depression, 
diabetes, or COPD was based on patients’ reports and not 
ascertained in the frame of the study. Moreover, cardiolo-
gists were asked to recruit patients consecutively, but did 
not complete a screening and enrolment log. Although they 
did not report any patients denying participation, patient 
selection may have been biased by factors unaccounted 
for in this study. Finally, PrEP-participants were recruited 
between 2010 and 2012, when in general, diagnosis and 
management of co-morbidities received less attention than 
recommended in the most recent version of the European 
Society of Cardiology HF guidelines. Awareness of anae-
mia and ID as common characteristics of the HF syndrome 
with adverse impact on prognosis may since have increased 
also amongst physicians responsible for HF outpatient 
care. However, the PrEP registry results, derived from the 
so far largest stable outpatient cohort of symptomatic HF 
patients, provide for the first time strong arguments to diag-
nose and treat these conditions also in stable outpatients 
attending cardiologist practices, and appear suited to call 
cardiologists into responsibility in this respect. PrEP results 
may thus significantly reinforce routine assessment of iron 
status and help to establish iron supplementation as a treat-
ment option also in current ambulatory HF care.
Conclusions
The PReP registry, which involved a large cohort of 
patients with symptomatisc systolic HF enrolled in 42 Ger-
man office-based cardiology practices, demonstrated high 
prevalence of both anaemia and ID (18.9% and 42.5%, 
respectively) in this population. Despite this high preva-
lence, anaemia was often unappreciated, and ID was previ-
ously unknown in all PrEP-participants. Clinical relevance, 
treatability, and independent association with reduced 
physical performance as demonstrated by the PrEP results 
call for routine diagnostic clarification of anaemia and 
ID-screening in ambulatory healthcare settings to further 
improve current outpatient HF care.
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